Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Conference Call February 6, 2023 8:00 AM ET
Company Participants
Kevin Gorman - CEO
Matt Abernethy - CFO
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development and Strategy Officer
Todd Tushla - VP of IR
Conference Call Participants
Paul Matteis - Stifel
Neena Bitritto-Garg - Citi
Tazeen Ahmad - Bank of America
Brian Skorney - Baird
Phil Nadeau - Cowen & Company
Chris Shibutani - Goldman Sachs
Carter Gould - Barclays
Myles Minter - William Blair
Brian Abrahams - RBC Capital Markets
Jay Olson - Oppenheimer
Charles Duncan - Cantor Fitzgerald
Laura Chico - Wedbush Securities
Marc Goodman - SVB Securities
Ashwani Verma - UBS
David Amsellem - Piper Sandler
Evan Seigerman - BMO Capital Markets
Ami Fadia - Needham
Yatin Suneja - Guggenheim Partners
Sumant Kulkarni - Canaccord Genuity
Mohit Bansal - Wells Fargo
Operator
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year-End Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer period. [Operator Instructions]. Please note this call may be recorded, and I will be standing by should you need any assistance.
It is now my pleasure to turn the call over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Thank you, and a good Monday morning to everyone. Welcome to Neurocrine's fourth quarter and full year 2022 earnings call. I’m joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
During this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We will be jumping into Q&A after prepared remarks and as is customary, we will do our best to get to all of your questions.
With that, I'll turn things over to Kevin.
Kevin Gorman
Thank you, Todd, and good morning. Over the last several years, we have launched a number of initiatives to bring INGREZZA to TD patients and relieve their suffering. Now many of those initiatives have been very successful as evidenced most recently by the growth of INGREZZA in 2022 as we announced this morning. We’re going to continue to build on those efforts and anticipate continued meaningful growth in 2023 out into the foreseeable future.